[{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"10294ca2-7f84-44ce-af11-76cdd03b1746","acronym":"SERENA-2","url":"https://clinicaltrials.gov/study/NCT04214288","created_at":"2021-01-18T20:31:16.451Z","updated_at":"2025-02-25T14:40:27.343Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04214288 - SERENA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 04/22/2020","start_date":" 04/22/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-14"},{"id":"593bd291-2adc-49c4-bd0f-7562aaaad9cd","acronym":"RIBOLARIS","url":"https://clinicaltrials.gov/study/NCT05296746","created_at":"2022-03-26T00:55:02.980Z","updated_at":"2025-02-25T15:54:25.627Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer","source_id_and_acronym":"NCT05296746 - RIBOLARIS","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2025-02-04"},{"id":"877e6060-0685-49ad-bf87-696fb090b715","acronym":"","url":"https://clinicaltrials.gov/study/NCT03218826","created_at":"2021-01-18T15:52:53.855Z","updated_at":"2025-02-25T16:51:57.310Z","phase":"Phase 1","brief_title":"PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03218826","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PTEN • PIK3CB","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AZD8186"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 07/25/2022","primary_completion_date":" 07/25/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-04"},{"id":"55cb45be-28da-426b-95b0-c684a21c9966","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311933","created_at":"2021-01-18T10:56:52.952Z","updated_at":"2025-02-25T16:58:44.113Z","phase":"Phase 2","brief_title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02311933","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • NCOA3","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["ER • NCOA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/28/2015","start_date":" 05/28/2015","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 02/04/2025","study_completion_date":" 02/04/2025","last_update_posted":"2025-02-03"},{"id":"469f79f5-7bed-470f-bde8-dd6a3a9d7203","acronym":"GO39932","url":"https://clinicaltrials.gov/study/NCT03332797","created_at":"2021-01-17T18:03:30.772Z","updated_at":"2024-07-02T16:34:37.744Z","phase":"Phase 1","brief_title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT03332797 - GO39932","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-06"},{"id":"ce41ba1f-4d4f-4c72-ae06-d61cb6cc53c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04546009","created_at":"2021-01-18T21:44:38.264Z","updated_at":"2024-07-02T16:34:58.754Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","source_id_and_acronym":"NCT04546009","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 992","initiation":"Initiation: 10/09/2020","start_date":" 10/09/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/18/2027","study_completion_date":" 03/18/2027","last_update_posted":"2024-06-05"},{"id":"b2165e76-d0e7-44ca-a80d-0a76836cbb19","acronym":"","url":"https://clinicaltrials.gov/study/NCT03366844","created_at":"2021-01-18T16:37:01.627Z","updated_at":"2024-07-02T16:35:03.976Z","phase":"Phase 1/2","brief_title":"Breast Cancer Study of Preoperative Pembrolizumab + Radiation","source_id_and_acronym":"NCT03366844","lead_sponsor":"Stephen Shiao","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/22/2017","start_date":" 12/22/2017","primary_txt":" Primary completion: 12/03/2024","primary_completion_date":" 12/03/2024","study_txt":" Completion: 04/21/2025","study_completion_date":" 04/21/2025","last_update_posted":"2024-05-14"},{"id":"b9da037d-37b3-4bac-941c-5f2331877777","acronym":"FESTA","url":"https://clinicaltrials.gov/study/NCT05982496","created_at":"2023-08-08T14:08:47.611Z","updated_at":"2024-07-02T16:35:04.856Z","phase":"","brief_title":"18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer","source_id_and_acronym":"NCT05982496 - FESTA","lead_sponsor":"Università Vita-Salute San Raffaele","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 221","initiation":"Initiation: 10/15/2024","start_date":" 10/15/2024","primary_txt":" Primary completion: 05/15/2027","primary_completion_date":" 05/15/2027","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-05-08"},{"id":"ed1d3e55-87fe-4b46-bab6-272b2186f25b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06126003","created_at":"2023-11-13T20:15:20.456Z","updated_at":"2024-07-02T16:35:11.004Z","phase":"","brief_title":"Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.","source_id_and_acronym":"NCT06126003","lead_sponsor":"BioCorteX Inc","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/13/2024","primary_completion_date":" 12/13/2024","study_txt":" Completion: 01/13/2025","study_completion_date":" 01/13/2025","last_update_posted":"2024-04-08"},{"id":"a3f61bfa-b568-4170-9370-35695b363767","acronym":"","url":"https://clinicaltrials.gov/study/NCT05474391","created_at":"2022-07-26T17:10:05.279Z","updated_at":"2024-07-02T16:35:17.685Z","phase":"","brief_title":"MammaPrint Value for Pre-menopausal Breast Cancer Patients","source_id_and_acronym":"NCT05474391","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-02-26"},{"id":"217787a8-8a1f-4b76-8e10-a1f5c3ed4830","acronym":"MECCA","url":"https://clinicaltrials.gov/study/NCT02767661","created_at":"2021-01-18T13:34:19.411Z","updated_at":"2024-07-02T16:35:19.049Z","phase":"Phase 3","brief_title":"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer","source_id_and_acronym":"NCT02767661 - MECCA","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • letrozole • anastrozole • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/19/2017","start_date":" 07/19/2017","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-02-16"},{"id":"a71dfb98-71e8-43d7-baba-9d5f54087356","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512364","created_at":"2022-08-23T14:55:35.137Z","updated_at":"2024-07-02T16:35:22.428Z","phase":"Phase 3","brief_title":"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","source_id_and_acronym":"NCT05512364","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 05/01/2030","study_completion_date":" 05/01/2030","last_update_posted":"2024-01-24"},{"id":"02eaa568-b3ce-4a18-a3ca-9ab426a744ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05132790","created_at":"2021-11-24T18:55:39.081Z","updated_at":"2024-07-02T16:35:24.664Z","phase":"","brief_title":"Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment","source_id_and_acronym":"NCT05132790","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • albumin-bound paclitaxel • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-03"},{"id":"bd544bf4-745a-4b82-abc5-b542c9fc7a34","acronym":"ROLo","url":"https://clinicaltrials.gov/study/NCT03620643","created_at":"2021-01-18T17:47:27.839Z","updated_at":"2024-07-02T16:35:25.368Z","phase":"Phase 2","brief_title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","source_id_and_acronym":"NCT03620643 - ROLo","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • CDH1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • CDH1 mutation • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-12-22"},{"id":"17777c0f-e001-4f8b-a754-cd01fa35a04f","acronym":"CCTG MA38","url":"https://clinicaltrials.gov/study/NCT02630693","created_at":"2021-01-18T12:47:32.319Z","updated_at":"2024-07-02T16:35:25.651Z","phase":"Phase 2","brief_title":"Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer","source_id_and_acronym":"NCT02630693 - CCTG MA38","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 04/08/2016","start_date":" 04/08/2016","primary_txt":" Primary completion: 08/15/2018","primary_completion_date":" 08/15/2018","study_txt":" Completion: 11/29/2023","study_completion_date":" 11/29/2023","last_update_posted":"2023-12-20"},{"id":"08ee410d-1895-4437-a341-a05a63facabe","acronym":"Abemacare","url":"https://clinicaltrials.gov/study/NCT04681768","created_at":"2021-01-19T20:46:48.153Z","updated_at":"2024-07-02T16:35:27.766Z","phase":"","brief_title":"Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT04681768 - Abemacare","lead_sponsor":"Technical University of Munich","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-29"},{"id":"68ced0d1-5116-4b3d-8079-1a15f3e6de8f","acronym":"FAIM","url":"https://clinicaltrials.gov/study/NCT04920708","created_at":"2021-06-11T00:54:37.032Z","updated_at":"2024-07-02T16:35:31.322Z","phase":"Phase 2","brief_title":"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression","source_id_and_acronym":"NCT04920708 - FAIM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation","tags":["HER-2 • ER • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • ipatasertib (RG7440) • Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-10-27"},{"id":"5bf752ff-70a9-47c7-a310-a358648ff849","acronym":"TIRESIAS","url":"https://clinicaltrials.gov/study/NCT04660435","created_at":"2021-01-19T20:42:27.155Z","updated_at":"2024-07-02T16:35:36.716Z","phase":"","brief_title":"To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer","source_id_and_acronym":"NCT04660435 - TIRESIAS","lead_sponsor":"Fondazione Sandro Pitigliani","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-09-18"},{"id":"d1a173eb-5c87-47d9-878f-9172b0439c3d","acronym":"PDM-MBC","url":"https://clinicaltrials.gov/study/NCT04597580","created_at":"2021-01-19T20:29:31.274Z","updated_at":"2024-07-02T16:35:38.865Z","phase":"","brief_title":"Personalised Disease Monitoring in Metastatic Breast Cancer","source_id_and_acronym":"NCT04597580 - PDM-MBC","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2023-08-28"},{"id":"6ed06cab-c7c7-450b-93d9-67848afd9e45","acronym":"CICLADES","url":"https://clinicaltrials.gov/study/NCT03318263","created_at":"2021-01-18T16:23:13.868Z","updated_at":"2024-07-02T16:35:40.862Z","phase":"","brief_title":"CIrCuLAting Dna ESr1 Gene Mutations Analysis","source_id_and_acronym":"NCT03318263 - CICLADES","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2 • ER • PIK3CA • AKT1","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • PIK3CA • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-08-04"},{"id":"a1c4255b-9384-4488-888f-05d0a9d1efc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05851092","created_at":"2023-05-09T14:04:36.919Z","updated_at":"2024-07-02T16:35:43.591Z","phase":"Phase 1","brief_title":"Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT05851092","lead_sponsor":"Shandong Suncadia Medicine Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRS-2189"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-07"},{"id":"c987f8f9-55ca-4446-b005-880b3d88e017","acronym":"NeoRHEA","url":"https://clinicaltrials.gov/study/NCT03065621","created_at":"2021-01-18T15:06:06.867Z","updated_at":"2024-07-02T16:35:50.183Z","phase":"Phase 2","brief_title":"Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)","source_id_and_acronym":"NCT03065621 - NeoRHEA","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 03/28/2019","primary_completion_date":" 03/28/2019","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2023-04-19"},{"id":"bb66e25f-8961-4f7e-810b-be1bb9f3fa55","acronym":"DARE","url":"https://clinicaltrials.gov/study/NCT04567420","created_at":"2021-01-18T21:49:00.485Z","updated_at":"2024-07-02T16:35:52.824Z","phase":"Phase 2","brief_title":"DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04567420 - DARE","lead_sponsor":"Criterium, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER negative • PGR positive • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER negative • PGR positive • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 02/09/2021","start_date":" 02/09/2021","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2023-03-21"}]